# GP-Plus

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/gp-plus
Canonical HTML page: https://getbiobrief.com/entity/gp-plus

## Recent coverage (1 stories)

### Roche's p-tau217 Blood Test Enters 500-Patient Primary Care Alzheimer's Trial
2026-07-20 05:51:26 · Sentiment: Bullish · Impact: 8/10 · Sources: 3

Roche Diagnostics' p-tau217 assay is being evaluated in a pragmatic trial across 50 Scottish GP practices, enrolling up to 500 patients. The BriDGe study could produce critical real-world evidence to support regulatory approval and companion diagnostic strategies for emerging Alzheimer's therapies.
Full story: https://getbiobrief.com/story/roche-p-tau217-alzheimers-primary-care-trial

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.